ARVO 2024: Feasibility and clinical efficacy of an OCT B-scan of interest tool
May 16th 2024ARVO
At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Niranchana Manivannan, PhD. She spoke about the poster presentation, "Feasibility and clinical efficacy of an OCT B-scan of interest tool."
ARVO 2024: Predicting 3-year myopia control efficacy from 1-year data
May 13th 2024ARVO
At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.
ARVO 2024: Post hoc analysis of phase 3 trial on SB15
May 8th 2024ARVO
At this year's ARVO meeting, SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."
ARVO 2024: Post-hoc analysis of GOBI and MOJAVE trials for perfluorohexyloctane
May 7th 2024ARVO
John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
ARVO 2024: Researchers drive innovation in retinal research
May 7th 2024ARVO
A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed diverse retina-related challenges and unveiled findings with the potential to revolutionize vision science.
ARVO 2024: Study validates ChatGPT 4.0 as potential uveitis patient resource
May 7th 2024ARVO
In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.